Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/11/2025 | $40.00 | Overweight | Stephens |
| 10/2/2025 | $30.00 | Hold | TD Cowen |
| 4/30/2025 | $40.00 | Neutral → Buy | UBS |
| 1/23/2025 | $26.00 → $35.00 | Hold → Buy | Jefferies |
| 1/13/2025 | $26.00 → $33.00 | Neutral → Buy | BofA Securities |
| 12/5/2024 | $26.00 | Neutral | UBS |
| 11/4/2024 | $27.00 | Buy → Neutral | Goldman |
| 10/31/2024 | $38.00 → $26.00 | Buy → Hold | Jefferies |
BANNOCKBURN, Ill., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Option Care Health, Inc. ("Option Care Health") (NASDAQ:OPCH), the nation's largest independent provider of home and alternate site infusion services, will participate in the 46th Annual TD Cowen Healthcare Conference, being held in Boston, MA, on Tuesday, March 3, 2026, including a fireside chat at 1:10pm ET. The webcast will be available online at https://investors.optioncarehealth.com. About Option Care Health Option Care Health is the nation's largest independent provider of home and alternate site infusion services. With over 8,000 team members including more than 5,000 clinicians, we work compassionately to elevate standards of c
BANNOCKBURN, Ill., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Option Care Health Inc. ("Option Care Health") (NASDAQ:OPCH), the nation's largest independent provider of home and alternate site infusion services, today announced that the company will release results for its fourth quarter and full year 2025 on Tuesday, February 24, 2026 before the market opens. In conjunction, the management team will host a conference call to review the results at 8:30 a.m. E.T. on the same day. Conference Call DetailsParticipants can pre-register for the conference call at the following link: https://register-conf.media-server.com/register/BIf3f7a42783bf4a85aae626ffa262fb95. The call can also be accessed via a li
BANNOCKBURN, Ill., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the "Company" or "Option Care Health") (NASDAQ:OPCH), the nation's largest independent provider of home and alternate site infusion services, announced today preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025, and preliminary financial guidance for the full year 2026. (Year-over-year comparisons unless otherwise noted; Growth comparisons versus midpoint of range) Fourth Quarter 2025 Preliminary Expected Results Net revenue of $1.46 billion to $1.47 billionGAAP net income of $59.1 million to $62.4 millionGAAP diluted EPS of $0.37 to $0.39Adjusted diluted EPS of
8-K - Option Care Health, Inc. (0001014739) (Filer)
SCHEDULE 13G - Option Care Health, Inc. (0001014739) (Subject)
10-Q - Option Care Health, Inc. (0001014739) (Filer)
Stephens initiated coverage of Option Care Health with a rating of Overweight and set a new price target of $40.00
TD Cowen initiated coverage of Option Care Health with a rating of Hold and set a new price target of $30.00
UBS upgraded Option Care Health from Neutral to Buy and set a new price target of $40.00
4 - Option Care Health, Inc. (0001014739) (Issuer)
4 - Option Care Health, Inc. (0001014739) (Issuer)
4 - Option Care Health, Inc. (0001014739) (Issuer)
4 - Option Care Health, Inc. (0001014739) (Issuer)
4 - Option Care Health, Inc. (0001014739) (Issuer)
3 - Option Care Health, Inc. (0001014739) (Issuer)
BANNOCKBURN, Ill., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Option Care Health Inc. ("Option Care Health") (NASDAQ:OPCH), the nation's largest independent provider of home and alternate site infusion services, today announced that the company will release results for its fourth quarter and full year 2025 on Tuesday, February 24, 2026 before the market opens. In conjunction, the management team will host a conference call to review the results at 8:30 a.m. E.T. on the same day. Conference Call DetailsParticipants can pre-register for the conference call at the following link: https://register-conf.media-server.com/register/BIf3f7a42783bf4a85aae626ffa262fb95. The call can also be accessed via a li
BANNOCKBURN, Ill., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the "Company" or "Option Care Health") (NASDAQ:OPCH), the nation's largest independent provider of home and alternate site infusion services, announced today financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights (Year-over-year comparisons unless otherwise noted) Net revenue of $1,435.0 million, up 12.2%Gross profit of $272.9 million, up 6.3%Net income of $51.8 million, down 3.8%GAAP diluted earnings per share of $0.32, up 3.2%Adjusted EBITDA of $119.5 million, up 3.4%Adjusted diluted earnings per share of $0.45, up 9.8%YTD cash provided by operating activit
BANNOCKBURN, Ill., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Option Care Health Inc. ("Option Care Health") (NASDAQ: OPCH), the nation's largest independent provider of home and alternate site infusion services, today announced that the company will release results for its third quarter ended September 30, 2025 on Thursday, October 30, 2025 before the market opens. In conjunction, the management team will host a conference call to review the results at 8:30 a.m. E.T. on the same day. Conference Call DetailsParticipants can pre-register for the conference call at the following link: https://register-conf.media-server.com/register/BI9e5bd109ef23408dbd76380aed8d4b05. The call can also be accessed v
SC 13G - Option Care Health, Inc. (0001014739) (Subject)
SC 13G/A - Option Care Health, Inc. (0001014739) (Subject)
SC 13G/A - Option Care Health, Inc. (0001014739) (Subject)
BANNOCKBURN, Ill., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the "Company" or "Option Care Health") (NASDAQ:OPCH), the nation's largest independent provider of home and alternate site infusion services, announced the appointment of Meenal Sethna as Executive Vice President and Chief Financial Officer, effective October 1, 2025. Sethna will succeed Mike Shapiro, who has decided to step down as CFO effective September 30, 2025, following a decade of service to the Company. At the time of the transition, Shapiro will remain with the Company as a Strategic Advisor through at least the first quarter of 2026 to continue to help advance the Company's strategy and ensure a smooth
Marks major milestone with completion of enrollment in pivotal Phase 3 NEAT clinical trial evaluating lead asset, eDSP, for the treatment of A-T; topline results expected in first quarter of 2026 Closed financing priced at a premium bringing existing cash position to approximately $35 million; expected to provide runway through Phase 3 topline results and into at least second quarter of 2026 Entered into strategic relationship with Option Care Health to support commercial launch of eDSP in the U.S. Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today provided an
NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024. Following these appointments, the Board will comprise of 8 directors, 5 of whom are non-executive. "We are pleased to welcome Barbara and David to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Barbara's deep experience serving in senior finance and board roles in leading edge pharmaceutical and